Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus : a review. / Østergaard, L; Frandsen, Christian S.; Madsbad, S.

I: Expert Review of Clinical Pharmacology, Bind 9, Nr. 2, 2016, s. 241-65.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Østergaard, L, Frandsen, CS & Madsbad, S 2016, 'Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review', Expert Review of Clinical Pharmacology, bind 9, nr. 2, s. 241-65. https://doi.org/10.1586/17512433.2016.1121808

APA

Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016). Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology, 9(2), 241-65. https://doi.org/10.1586/17512433.2016.1121808

Vancouver

Østergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology. 2016;9(2):241-65. https://doi.org/10.1586/17512433.2016.1121808

Author

Østergaard, L ; Frandsen, Christian S. ; Madsbad, S. / Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus : a review. I: Expert Review of Clinical Pharmacology. 2016 ; Bind 9, Nr. 2. s. 241-65.

Bibtex

@article{4ddb0a54efa649e3bdf866234307f289,
title = "Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review",
abstract = "Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.",
keywords = "Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Insulin, Journal Article, Review",
author = "L {\O}stergaard and Frandsen, {Christian S.} and S Madsbad",
year = "2016",
doi = "10.1586/17512433.2016.1121808",
language = "English",
volume = "9",
pages = "241--65",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus

T2 - a review

AU - Østergaard, L

AU - Frandsen, Christian S.

AU - Madsbad, S

PY - 2016

Y1 - 2016

N2 - Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.

AB - Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.

KW - Animals

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucagon-Like Peptide-1 Receptor

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin

KW - Journal Article

KW - Review

U2 - 10.1586/17512433.2016.1121808

DO - 10.1586/17512433.2016.1121808

M3 - Review

C2 - 26573176

VL - 9

SP - 241

EP - 265

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 2

ER -

ID: 176702269